Weijing Sun, MD is Professor of Medicine, Director of GI Cancer of the Hematology-Oncology Division, and Co-Director of UPMC Gastrointestinal Cancer Center of Excellence at the University of Pittsburgh Cancer Institute.
His focus is on the treatment and clinical research of GI malignances, mainly on the development of new drugs and biologic/targeted oriented agents in treatment/therapy (including translational research) of gastrointestinal malignances with great experience in the early phase clinical trials (phase I, II) by designing, developing and conducting clinical trials, many of which have been published.
He has authored many publications including original clinical research articles, reviews, and invited editorial commends in a variety of peer-reviewed journals. He has also written chapters as a GI oncology expert for several medical textbooks including WebMD, Textbook of Gastroenterology. He has had more than 90 publications. He is serving as a member of editorial boards or review committees for several professional journals, including Clinical Colorectal Cancer, Journal of Clinical Gastroenterology, Journal of Clinical Oncology, Cancer, Disease of the Colon and Rectum, Cancer Biology and Therapy, Expert Opinion on Investigational Drugs, Pharmacogenomics, Gastroenterology, Expert Review of Anticancer Therapy, American Journal of Hematology-Oncology.
As a member of ECOG GI Core Committee, he has a significant role in many ECOG studies’ design, review, and approval processing. He has been served as PI for many investigator initiated studies and pharmaceutical companies’ trials. He has been serving as a member of NCI (National Cancer Institute) GI Steering Committee Hepato-biliary Task Force.
He is an active member in the American College of Physicians, American Medical Association, American Society of Clinical Oncology, American Association for Cancer Research, and the Eastern Cooperative Group of Oncology.
He has been named as a ‘Top-doctor’ by US News.